» Articles » PMID: 35158874

Machine Learning and Deep Learning Applications in Multiple Myeloma Diagnosis, Prognosis, and Treatment Selection

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2022 Feb 15
PMID 35158874
Authors
Affiliations
Soon will be listed here.
Abstract

Artificial intelligence has recently modified the panorama of oncology investigation thanks to the use of machine learning algorithms and deep learning strategies. Machine learning is a branch of artificial intelligence that involves algorithms that analyse information, learn from that information, and then employ their discoveries to make abreast choice, while deep learning is a field of machine learning basically represented by algorithms inspired by the organization and function of the brain, named artificial neural networks. In this review, we examine the possibility of the artificial intelligence applications in multiple myeloma evaluation, and we report the most significant experimentations with respect to the machine and deep learning procedures in the relevant field. Multiple myeloma is one of the most common haematological malignancies in the world, and among them, it is one of the most difficult ones to cure due to the high occurrence of relapse and chemoresistance. Machine learning- and deep learning-based studies are expected to be among the future strategies to challenge this negative-prognosis tumour via the detection of new markers for their prompt discovery and therapy selection and by a better evaluation of its relapse and survival.

Citing Articles

Big data analytics and machine learning in hematology: Transformative insights, applications and challenges.

Obeagu E, Ezeanya C, Ogenyi F, Ifu D Medicine (Baltimore). 2025; 104(10):e41766.

PMID: 40068020 PMC: 11902945. DOI: 10.1097/MD.0000000000041766.


Predicting the Progression from Asymptomatic to Symptomatic Multiple Myeloma and Stage Classification Using Gene Expression Data.

Karathanasis N, Spyrou G Cancers (Basel). 2025; 17(2).

PMID: 39858113 PMC: 11764453. DOI: 10.3390/cancers17020332.


Artificial intelligence: clinical applications and future advancement in gastrointestinal cancers.

Akbari A, Adabi M, Masoodi M, Namazi A, Mansouri F, Tabaeian S Front Artif Intell. 2025; 7:1446693.

PMID: 39764458 PMC: 11701808. DOI: 10.3389/frai.2024.1446693.


Common laboratory results-based artificial intelligence analysis achieves accurate classification of plasma cell dyscrasias.

Yao B, Liu Y, Wu Y, Mao S, Zhang H, Jiang L PeerJ. 2024; 12:e18391.

PMID: 39512310 PMC: 11542560. DOI: 10.7717/peerj.18391.


Recent advances in imaging and artificial intelligence (AI) for quantitative assessment of multiple myeloma.

Liu Y, Huang W, Yang Y, Cai W, Sun Z Am J Nucl Med Mol Imaging. 2024; 14(4):208-229.

PMID: 39309415 PMC: 11411189. DOI: 10.62347/NLLV9295.


References
1.
Kumar S, Rajkumar S . Many facets of bortezomib resistance/susceptibility. Blood. 2008; 112(6):2177-8. DOI: 10.1182/blood-2008-07-167767. View

2.
Kumar S, Kaufman J, Gasparetto C, Mikhael J, Vij R, Pegourie B . Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood. 2017; 130(22):2401-2409. DOI: 10.1182/blood-2017-06-788786. View

3.
Mosquera Orgueira A, Gonzalez Perez M, Diaz Arias J, Antelo Rodriguez B, Alonso Vence N, Bendana Lopez A . Survival prediction and treatment optimization of multiple myeloma patients using machine-learning models based on clinical and gene expression data. Leukemia. 2021; 35(10):2924-2935. DOI: 10.1038/s41375-021-01286-2. View

4.
Moreaux J, Klein B, Bataille R, Descamps G, Maiga S, Hose D . A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines. Haematologica. 2010; 96(4):574-82. PMC: 3069235. DOI: 10.3324/haematol.2010.033456. View

5.
Suzuki K . Latest treatment strategies aiming for a cure in transplant-eligible multiple myeloma patients: how I cure younger MM patients with lower cost. Int J Hematol. 2020; 111(4):512-518. DOI: 10.1007/s12185-020-02841-w. View